Stifel Financial: IB Leads The Way Despite March Dealmaking Snag

Stifel Financial Corp. had decent results from pro-volatility businesses but even better results from businesses otherwise more threatened by the dealmaking slump. There may be some pause after Q1 in biotech depositories, but the decent market environment despite the Iran War may not threaten capital raising and industrial advisory too much. Growth should still be possible, though we wouldn't be surprised by some deceleration, even if overall dealmaking is supposed to have recovered, possibly driven by large tickets, though.